pix11: ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and HAMMOND, La., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, ...
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
RAMSEY, N.J. and BOCA RATON, Fla., (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company ...
Seeking Alpha: ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company’s key product, ASCENIV, is expected to drive ...
Seeking Alpha: ADMA Biologics: Optionality With SG-001 And A Vertically Integrated IG Platform
ADMA’s growth remains centered on Asceniv, Bivigam, and NABI-HB. These are its main value drivers today. ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma ...
Fighting Junk Email Microsoft's email safety roadmap involves an unmatched cross-product approach. SmartScreen® anti-spam and anti-phishing filtering technology is being applied across Microsoft's email platforms to provide customers with the latest anti-spam and anti-phishing tools and innovations throughout the network. These products include Outlook.com, Exchange, Office 365, and more. The ...
MarketWatch: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research
The MarketWatch News Department was not involved in the creation of this content. Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business ...